Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology

被引：12

作者：

Amemiya, Takahiro ^{[1
]}

Honma, Masashi ^{[1
,2
]}

Kariya, Yoshiaki ^{[1
]}

Ghosh, Samik ^{[3
]}

Kitano, Hiroaki ^{[3
,4
,5
,6
]}

Kurachi, Yoshihisa ^{[7
]}

Fujita, Ken-ichi ^{[8
]}

Sasaki, Yasutsuna ^{[8
,9
]}

Homma, Yukio ^{[10
]}

Abernethy, Darrel R. ^{[11
]}

Kume, Haruki ^{[10
]}

Suzuki, Hiroshi ^{[1
]}

机构：

[1] Univ Tokyo, Univ Tokyo Hosp, Dept Pharm, Fac Med, Tokyo, Japan

[2] Univ Tokyo, Univ Tokyo Hosp, Lab Pharmacol & Pharmacokinet, Fac Med, Tokyo, Japan

[3] Syst Biol Inst, Tokyo, Japan

[4] Okinawa Inst Sci & Technol, Integrated Open Syst Unit, Onna, Okinawa, Japan

[5] Sony Comp Sci Labs Inc, Tokyo, Japan

[6] RIKEN, Ctr Integrat Med Sci, Lab Dis Syst Modeling, Yokohama, Kanagawa, Japan

[7] Osaka Univ, Grad Sch Med, Dept Pharmacol, Osaka, Japan

[8] Showa Univ, Inst Mol Oncol, Tokyo, Japan

[9] Showa Univ, Div Med Oncol, Dept Med, Sch Med, Tokyo, Japan

[10] Univ Tokyo, Univ Tokyo Hosp, Dept Urol, Fac Med, Tokyo, Japan

[11] US FDA, Off Clin Pharmacol, Off Translat Sci, Silver Spring, MD USA

来源：

NPJ SYSTEMS BIOLOGY AND APPLICATIONS | 2015年 / 1卷

基金：

日本学术振兴会;

关键词：

TYROSINE KINASE; PHOSPHORYLASE-KINASE; GLYCOGEN-METABOLISM; PROTEIN-KINASE; MANAGEMENT; SUNITINIB; GENE; RAT; SORAFENIB; TOXICITY;

D O I：

10.1038/npjsba.2015.5

中图分类号：

Q [生物科学];

学科分类号：

090105 [作物生产系统与生态工程];

摘要：

BACKGROUND/OBJECTIVES: Targeted kinase inhibitors are an important class of agents in anticancer therapeutics, but their limited tolerability hampers their clinical performance. Identification of the molecular mechanisms underlying the development of adverse reactions will be helpful in establishing a rational method for the management of clinically adverse reactions. Here, we selected sunitinib as a model and demonstrated that the molecular mechanisms underlying the adverse reactions associated with kinase inhibitors can efficiently be identified using a systems toxicological approach. METHODS: First, toxicological target candidates were short-listed by comparing the human kinase occupancy profiles of sunitinib and sorafenib, and the molecular mechanisms underlying adverse reactions were predicted by sequential simulations using publicly available mathematical models. Next, to evaluate the probability of these predictions, a clinical observation study was conducted in six patients treated with sunitinib. Finally, mouse experiments were performed for detailed confirmation of the hypothesized molecular mechanisms and to evaluate the efficacy of a proposed countermeasure against adverse reactions to sunitinib. RESULTS: In silico simulations indicated the possibility that sunitinib-mediated off-target inhibition of phosphorylase kinase leads to the generation of oxidative stress in various tissues. Clinical observations of patients and mouse experiments confirmed the validity of this prediction. The simulation further suggested that concomitant use of an antioxidant may prevent sunitinib-mediated adverse reactions, which was confirmed in mouse experiments. CONCLUSIONS: A systems toxicological approach successfully predicted the molecular mechanisms underlying clinically adverse reactions associated with sunitinib and was used to plan a rational method for the management of these adverse reactions.

引用

页数：10

共 53 条

[1]

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [J].